RDY — DR REDDYS LABORATORIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1135951 ·
India
Last close
$12.25
Market Cap
$10.20B
52W High
$15.56
52W Low
$11.28
ADV30
2,696,650
Next earnings
2026-10-23
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 80,705,000,000 | 37,540,000,000 | 3,033,000,000 | 4,435,000,000 | 575,305,000,000 | 11,204,000,000 | 188,570,000,000 |
| Mar 2026 | 75,162,000,000 | 43,035,000,000 | 829,000,000 | 2,209,000,000 | 579,346,000,000 | 15,368,000,000 | 198,889,000,000 |
| Dec 2025 | 87,268,000,000 | 46,806,000,000 | 14,330,000,000 | 12,098,000,000 | 562,899,000,000 | 18,657,000,000 | 187,143,000,000 |
| Sep 2025 | 88,051,000,000 | 48,140,000,000 | 17,867,000,000 | 14,372,000,000 | 542,005,000,000 | 9,906,000,000 | 179,923,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,199,000,000
Investing CF
$-42,485,000,000
Financing CF
$2,376,000,000
CapEx
$-31,980,000,000
Dividends Paid
$-6,659,000,000
Buybacks
—
EPS Diluted TTM
$39.74
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$356,419,000,000
Inventory
$80,473,000,000
Receivables
$124,417,000,000
ST Investments
$70,223,000,000
EBIT TTM
$45,465,000,000
Pretax Income TTM
$41,302,000,000
Interest Exp TTM
$4,163,000,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$331,186,012,160
EBITDA
$54,671,998,976
Free Cash Flow
$-3,909,625,088
Enterprise Value
$53,188,354,048
Total Cash
$81,426,997,248
Total Debt
$71,951,998,976
Shares Out
832,988,625
Trailing EPS
$0.42
Book Value
$0.81
ROE
8.8%
ROA
4.0%
Div Yield
0.70%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 335,933,000,000 | 50,123,000,000 | 42,850,000,000 | 579,346,000,000 | 198,889,000,000 | 377,063,000,000 | 56,755,000,000 |
| Mar 2025 | 325,535,000,000 | 72,014,000,000 | 56,544,000,000 | 492,989,000,000 | 155,823,000,000 | 333,388,000,000 | 46,428,000,000 |
| Mar 2024 | 279,164,000,000 | 65,308,000,000 | 55,684,000,000 | 387,518,000,000 | 106,968,000,000 | 280,550,000,000 | 45,433,000,000 |
| Mar 2023 | 245,879,000,000 | 59,054,000,000 | 45,067,000,000 | 321,854,000,000 | 90,863,000,000 | 230,991,000,000 | 58,875,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.65
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $12.50 · spot: $12.59 · call volume: 23 · put volume: 7
Expected Move to 2026-12-18:
±$1.35
(10.73%) —
implied range
$11.24 –
$13.94
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | $10.22B | $195.09 | — |
| ELAN | Elanco Animal Health Inc | $11.14B | $22.31 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $9.31B | $65.92 | — |
| PTGX | Protagonist Therapeutics, Inc | $9.18B | $141.86 | — |
| CYTK | CYTOKINETICS INC | $8.99B | $64.66 | — |
News headlines (Yahoo Finance, 1h cache)
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
2026-08-25 17:26 · Yahoo
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
2026-08-04 05:39 · Yahoo
Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...
2026-07-28 01:01 · Yahoo
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
2026-07-23 14:38 · Yahoo
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
2026-07-22 17:06 · Yahoo
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
2026-07-12 21:02 · Yahoo
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
2026-06-26 15:10 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
2026-06-18 14:43 · Yahoo
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
2026-06-13 10:22 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
2026-06-05 14:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.